University Hospital Maastricht
- Address
- lock Available on a paid plan
Oncology and Respiratory Research
At University Hospital Maastricht, clinical trials in neoplasms and respiratory tract diseases focus on cancers such as small-cell lung cancer, non-small cell lung cancer, head and neck cancer, and lymphoma. These studies are designed to test new treatment options, compare them with current standards, and improve outcomes for people with advanced or difficult-to-treat disease.
- Evaluating new immunotherapy and targeted treatment approaches for lung cancer
- Comparing treatment strategies in head and neck cancer and lymphoma
- Studying better ways to extend survival and control disease progression
The research also includes personalized approaches for specific tumor features, reflecting a strong interest in matching treatment to the biology of each cancer.
Women’s Health and Gynecologic Cancer
The site’s Gynaecology department is involved in trials for cervical cancer and endometrial cancer, with a clear focus on refining treatment while preserving quality of life. These studies explore whether newer therapies can improve cancer control and, in selected patients, support fertility-sparing care.
- Testing treatment options for cervical cancer and mismatch-repair deficient endometrial cancer
- Assessing whether treatment can be effective while reducing long-term impact on fertility
- Improving outcomes after surgery in gynecologic oncology
This area of research combines cancer treatment with a patient-centered approach, especially for women who may benefit from less invasive life planning after therapy.
Digestive System and Neuroendocrine Research
Trials in digestive system diseases at University Hospital Maastricht include studies in colon cancer, chronic pancreatitis, and neuroendocrine tumours. The goal is to improve treatment effectiveness, relieve symptoms, and identify better ways to track disease behavior.
- Evaluating new treatment approaches for resectable colon cancer
- Studying pain relief in chronic pancreatitis
- Assessing treatment continuation strategies in neuroendocrine tumours
This research reflects both cancer-focused care and efforts to improve symptom management in long-term digestive conditions.
Cardiovascular and Thrombotic Studies
The cardiovascular diseases portfolio includes research on subclinical heart failure and proximal deep vein thrombosis. These trials aim to improve early cardiac remodeling, support better heart function, and evaluate whether new clot-busting treatment options can be both effective and safe.
- Testing strategies to reverse early changes in heart failure
- Assessing new treatment options for deep vein thrombosis
- Measuring safety and clinical benefit in vascular disease care
The research combines prevention-oriented cardiology with treatment development for patients at risk of serious vascular complications.
Immune, Infectious, and Transplant-Related Research
Clinical trials in immune system diseases and virus diseases address impaired immunity, kidney transplantation, and COVID-19. These studies are focused on improving immune responses, strengthening vaccine effectiveness, and supporting safer care for transplant recipients and other vulnerable groups.
- Studying how to improve COVID-19 vaccination responses in kidney transplant patients
- Exploring immune function in people with impaired immunity
- Supporting safer treatment choices for patients with complex immune needs
This area highlights practical research aimed at reducing infection-related risk while protecting long-term health.
Ear, Skin, and Diagnostic Research
The site also conducts studies in otorhinolaryngologic diseases, skin and connective tissue diseases, and analytical, diagnostic and therapeutic techniques. Research includes Menière's disease, actinic keratosis, and diagnostic work for carcinoma of unknown primary.
- Testing symptom relief strategies for Menière's disease
- Evaluating treatment for actinic keratosis on the face or scalp
- Improving diagnostic methods to identify the origin of unknown primary cancer
These trials combine everyday clinical care with efforts to improve diagnosis and local disease control across several specialty areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 29 therapeutic areas and 15 of 381 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 365 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 72 by active trials.
- 1Amsterdam UMC Stichting11active
lock +71 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC14trials
lock +43 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Hospital Maastricht
lock Showing 1 of 269 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE) | Myokardia Inc. | Phase III | Not Recruiting | Sep 2019 | Jan 2026 |
IMP list
lock Showing 1 of 381 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 25 | Unknown | 2015-07-16 | 2026-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
